Papers, explained in our own words

1. A structure-based virtual screening-driven discovery pharmaceutics platform for cancer therapeutics development: FDA 505(b)(2) repurposing of netupitant as a BMX-targeted nanomedicine using quality-by-design lipid nanoparticles and model-informed PBPK translation

Singirikonda M, Patel T, Parupathi P, Nagarajan A, Patel Js, Devarakonda L, Et Al.

Bone marrow tyrosine kinase on chromosome X (BMX) is an emerging therapeutic target implicated in prostate cancer progression, metastatic disease, and resistance to current therapies; however, no selective BMX-targeted therapy has advanced to clinical development.

• Artificial intelligence
• Bone marrow tyrosine kinase on chromosome X (BMX)
• Cancer therapeutics
• Discovery pharmaceutics
• Drug repurposing
• FDA 505(b)(2)
• Lipid nanoparticles (LNPs)
• Model-informed drug development (MIDD)
• Physiologically based pharmacokinetic (PBPK) modeling